Recent advances in understanding the role of HES6 in cancers.


Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
2022
Historique:
received: 17 03 2022
accepted: 06 05 2022
entrez: 8 6 2022
pubmed: 9 6 2022
medline: 10 6 2022
Statut: epublish

Résumé

The NOTCH signaling system regulates a variety of cellular processes during embryonic development and homeostasis maintenance in different tissues and contexts. Hence, dysregulation of NOTCH signaling is associated with a plethora of human cancers, and there have been multiple efforts to target key components of this pathway. In this review, we briefly highlight the latest research advances in understanding HES6, a poorly studied component of the NOTCH pathway. We summarize the role of HES6 in cancers with a focus on uveal melanoma. Finally, we discuss the ongoing efforts to target the NOTCH-HES6 axis in cancers.

Identifiants

pubmed: 35673577
doi: 10.7150/thno.72966
pii: thnov12p4374
pmc: PMC9169368
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
HES6 protein, human 0
Repressor Proteins 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4374-4385

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

Mol Cancer Ther. 2017 Dec;16(12):2759-2769
pubmed: 28978720
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):244-9
pubmed: 19118200
Genomics. 1998 Apr 1;49(1):69-75
pubmed: 9570950
Cancer Res. 2011 Sep 15;71(18):6030-9
pubmed: 21795478
JNCI Cancer Spectr. 2018 Jul 23;2(3):pky032
pubmed: 31360859
Anticancer Res. 2011 Apr;31(4):1105-13
pubmed: 21508353
Cancer Cell. 2010 Jul 13;18(1):23-38
pubmed: 20609350
Oncogene. 2005 Oct 27;24(47):7073-83
pubmed: 16103883
Sci Adv. 2019 Sep 18;5(9):eaax1738
pubmed: 31555735
Math Biosci Eng. 2021 May 10;18(4):4055-4070
pubmed: 34198425
Science. 2004 Oct 8;306(5694):269-71
pubmed: 15472075
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6
pubmed: 17114293
J Cancer. 2019 Jun 2;10(14):3172-3178
pubmed: 31289587
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Ophthalmol Clin North Am. 2005 Mar;18(1):75-84, viii
pubmed: 15763193
Oncotarget. 2016 Feb 16;7(7):7610-28
pubmed: 26713603
Melanoma Res. 2007 Dec;17(6):380-6
pubmed: 17992121
Mol Cell Biol. 2003 Oct;23(19):6922-35
pubmed: 12972610
Dev Dyn. 2006 Jun;235(6):1689-700
pubmed: 16534784
Cancer Discov. 2015 Feb;5(2):198-211
pubmed: 25432929
Cell. 1998 May 15;93(4):649-60
pubmed: 9604939
Carcinogenesis. 2013 Jul;34(7):1420-30
pubmed: 23585460
Cancer Cell. 2012 Sep 11;22(3):373-88
pubmed: 22975379
Oncol Rep. 2018 Sep;40(3):1261-1274
pubmed: 30015909
Development. 2019 Oct 23;146(20):
pubmed: 31558434
Mol Cancer. 2020 Dec 5;19(1):170
pubmed: 33276788
J Exp Med. 2011 Sep 26;208(10):1963-76
pubmed: 21875955
Adv Exp Med Biol. 2021;1287:81-103
pubmed: 33034028
Sci Signal. 2014 Dec 23;7(357):ra121
pubmed: 25538079
Cell Mol Neurobiol. 2016 Jan;36(1):57-67
pubmed: 26105991
Annu Rev Pathol. 2017 Jan 24;12:245-275
pubmed: 27959635
Nat Commun. 2021 Sep 13;12(1):5402
pubmed: 34518527
Expert Rev Endocrinol Metab. 2008 Jan;3(1):91-100
pubmed: 30743788
Pharmacol Ther. 2017 Jun;174:138-144
pubmed: 28223226
Breast Cancer Res. 2009;11(6):R79
pubmed: 19891787
Nucleic Acids Res. 2007;35(14):4583-96
pubmed: 17586813
Cancer Cell. 2014 Jun 16;25(6):831-45
pubmed: 24882515
Biochem Biophys Res Commun. 2005 Jun 24;332(1):33-6
pubmed: 15896295
Nat Commun. 2020 Jan 24;11(1):496
pubmed: 31980621
J Cell Biol. 2001 Sep 17;154(6):1161-71
pubmed: 11551980
J Cell Sci. 2013 Jan 15;126(Pt 2):393-401
pubmed: 23525005
EMBO Mol Med. 2014 May 01;6(5):651-61
pubmed: 24737870
Br J Cancer. 2016 Nov 8;115(10):1245-1252
pubmed: 27755532
Nat Med. 2014 Oct;20(10):1130-7
pubmed: 25194570
Prog Retin Eye Res. 2021 Nov;85:100968
pubmed: 33852963
Cell. 2009 Apr 17;137(2):216-33
pubmed: 19379690
Cell Biochem Funct. 2019 Jan;37(1):21-30
pubmed: 30604499
Genes Cells. 2001 Feb;6(2):175-85
pubmed: 11260262
Trends Cell Biol. 2012 May;22(5):257-65
pubmed: 22397947
Front Cell Dev Biol. 2020 Dec 16;8:566932
pubmed: 33681178
Front Oncol. 2014 Dec 04;4:345
pubmed: 25538890
Dev Biol. 2004 Dec 1;276(1):47-63
pubmed: 15531363
PLoS One. 2011;6(11):e27880
pubmed: 22114720
Development. 2002 May;129(9):2195-207
pubmed: 11959828
Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1679-84
pubmed: 11431428
N Engl J Med. 2021 Sep 23;385(13):1196-1206
pubmed: 34551229
Theranostics. 2017 Apr 3;7(6):1447-1462
pubmed: 28529629
Int J Mol Med. 2020 Feb;45(2):279-297
pubmed: 31894255
Invest Ophthalmol Vis Sci. 2013 Jan 09;54(1):295-306
pubmed: 23211831
Oncologist. 2021 Apr;26(4):e608-e621
pubmed: 33284507
Nature. 2006 Dec 21;444(7122):1083-7
pubmed: 17183323
EMBO J. 2001 Jul 2;20(13):3427-36
pubmed: 11432830
J Invest Dermatol. 2016 Feb;136(2):464-472
pubmed: 26967479
Eur J Cancer. 2013 Nov;49(16):3559-72
pubmed: 23916913
Development. 2000 Jul;127(13):2933-43
pubmed: 10851137
Exp Cell Res. 2011 Jul 1;317(11):1590-602
pubmed: 21501606
Development. 2000 Oct;127(19):4203-16
pubmed: 10976052
Science. 2002 Oct 25;298(5594):840-3
pubmed: 12399594
Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):132-143
pubmed: 29332125
Curr Top Dev Biol. 2010;92:73-129
pubmed: 20816393
J Neurosci. 2006 Oct 25;26(43):11061-71
pubmed: 17065448
Int Ophthalmol. 2019 Dec;39(12):2825-2832
pubmed: 31161335
Development. 2007 Apr;134(7):1243-51
pubmed: 17329370
Cancer Cell. 2009 Jul 7;16(1):55-66
pubmed: 19573812
Nat Med. 2014 Oct;20(10):1199-205
pubmed: 25194568
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
J Clin Oncol. 2005 Nov 1;23(31):8076-80
pubmed: 16258106
Mech Dev. 2000 Jul;95(1-2):275-8
pubmed: 10906477
Cancer Lett. 2003 Aug 20;198(2):229-39
pubmed: 12957362
Exp Cell Res. 2013 Jan 1;319(1):103-12
pubmed: 22982728
Ernst Schering Found Symp Proc. 2007;(4):35-53
pubmed: 18811052
Cancer Res. 2007 Dec 1;67(23):11244-53
pubmed: 18056450
Cell Res. 1999 Sep;9(3):179-88
pubmed: 10520600
Acta Ophthalmol. 2018 Aug;96(5):503-509
pubmed: 29338117
Nat Rev Mol Cell Biol. 2016 Nov;17(11):722-735
pubmed: 27507209
N Biotechnol. 2017 Oct 25;39(Pt B):215-221
pubmed: 28842360
Cell Death Discov. 2020 Apr 17;6:22
pubmed: 32337074
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):E2939-48
pubmed: 23019585
BMC Med Genomics. 2008 May 19;1:17
pubmed: 18489756
Cancer Cell. 2016 Jun 13;29(6):889-904
pubmed: 27265506
Nat Genet. 2019 Jul;51(7):1123-1130
pubmed: 31253977
Am J Pathol. 2010 Apr;176(4):2019-28
pubmed: 20167860
Oncogene. 2012 Mar 8;31(10):1299-310
pubmed: 21785461
Nat Commun. 2017 Jan 16;8:14049
pubmed: 28091601
EMBO Mol Med. 2017 Jul;9(7):950-966
pubmed: 28539479
Cell Rep. 2019 May 7;27(6):1934-1947.e5
pubmed: 31067475
J Virol. 2003 Jun;77(12):7106-12
pubmed: 12768030
Clin Cancer Res. 2012 Feb 1;18(3):654-65
pubmed: 22228632
Oncol Rep. 2015 Jul;34(1):295-301
pubmed: 25955651
Development. 2007 Aug;134(15):2709-18
pubmed: 17611219
Oncotarget. 2016 Nov 1;7(44):71211-71222
pubmed: 27655717
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Cancer Res. 2006 May 1;66(9):4602-9
pubmed: 16651410
Front Oncol. 2019 Nov 18;9:1248
pubmed: 31803621
Cell Death Differ. 2021 Jun;28(6):1990-2000
pubmed: 33462406

Auteurs

Imène Krossa (I)

Université Côte d'Azur, France.
Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France.

Thomas Strub (T)

Université Côte d'Azur, France.
Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France.

Arnaud Martel (A)

Université Côte d'Azur, France.
Centre Hospitalier Universitaire de Nice, Department of Ophthalmology, Nice, France.

Sacha Nahon-Esteve (S)

Université Côte d'Azur, France.
Centre Hospitalier Universitaire de Nice, Department of Ophthalmology, Nice, France.

Sandra Lassalle (S)

Université Côte d'Azur, France.
Laboratoire de Pathologie clinique et expérimentale, biobanque BB-0033-00025, and IRCAN team 4, FHU OncoAge, Nice, France.

Paul Hofman (P)

Université Côte d'Azur, France.
Laboratoire de Pathologie clinique et expérimentale, biobanque BB-0033-00025, and IRCAN team 4, FHU OncoAge, Nice, France.

Stéphanie Baillif (S)

Université Côte d'Azur, France.
Centre Hospitalier Universitaire de Nice, Department of Ophthalmology, Nice, France.

Robert Ballotti (R)

Université Côte d'Azur, France.
Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France.

Corine Bertolotto (C)

Université Côte d'Azur, France.
Inserm, Biology and Pathologies of melanocytes, team1, Equipe labellisée Ligue 2020 and Equipe labellisée ARC 2019, Centre Méditerranéen de Médecine Moléculaire, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH